Concord Biotech Board Meeting on Oct 27 to Approve Q2 Results

Concord Biotech Ltd has announced that its Board of Directors will convene on Tuesday, October 27, 2026. The primary agenda item is the consideration and approval of the unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The Statutory Auditors will also issue their Limited Review Report. Concurrently, the trading window for the company's securities will remain closed until 48 hours after the declaration of these financial results, in adherence to SEBI (Prohibition of Insider Trading) Regulations, 2015.